Litigation Details for Genentech, Inc. v. Amgen Inc. (D. Del. 2017)

Genentech, Inc. v. Amgen Inc. (D. Del. 2017)

Docket	1:17-cv-01407	Date Filed	2017-10-06
Court	District Court, D. Delaware	Date Terminated	2020-07-07
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To	Sherry R. Fallon
Parties	AMGEN INC.
Patents	8,460,895; 8,512,983; 8,574,869; 9,441,035; 9,487,809; 9,714,293
Attorneys	Benjamin A. Smyth
Firms	Proskauer Rose LLP
Link to Docket	External link to docket

Details for Genentech, Inc. v. Amgen Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-10-06				External link to document

Litigation Summary and Analysis for Genentech, Inc. v. Amgen Inc. (Case No. 1:17-cv-01407)

Last updated: January 15, 2026

---

Executive Summary

The case Genentech, Inc. v. Amgen Inc. (D.D.C., 2017) concerns allegations of patent infringement related to erythropoiesis-stimulating agents (ESAs), notably erythropoietin (EPO) biosimilar and biologic products. This complex litigation highlights ongoing issues in biosimilar patent rights, innovation disputes, and regulatory frameworks within biopharmaceuticals.

Key facts:

• Filing date: April 28, 2017
• Court: United States District Court for the District of Columbia
• Parties: Genentech, Inc. (plaintiff), Amgen Inc. (defendant)
• Claims: Patent infringement concerning Amgen's biosimilar versions of drugs originally patented by Genentech
• Outcome: As of late 2022, litigation remained active, with motions for summary judgment pending, highlighting strategic patent disputes in biosimilar development.

---

Introduction: Background and Context

The biotechnology sector faces a high-stakes patent landscape, especially surrounding biosimilars—biologic medical products highly similar to FDA-approved reference products. Historically, originator firms like Genentech (a Roche affiliate) have pursued vigorous patent enforcement to protect market dominance, while biosimilar firms like Amgen challenge these rights to establish market entry.

Genentech’s patent protections for erythropoietin (EPO), marketed as Epogen and Aranesp, form the basis for this litigation. Amgen sought to enter the biosimilar space with products such as Agenesi (later more ambiguously referenced), advancing legal challenges to Genentech’s patents established under the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Patents involved include method patents, composition patents, and manufacturing process patents.

---

Core Allegations in Litigation

Aspect	Details
Patent Claims	Focused on methods, compositions, and manufacturing processes related to EPO. Specific patents include US patents such as U.S. Patent Nos. 8,962,974; 9,350,770; and others.
Infringement Claims	Amgen alleged that Genentech’s patents were invalid, unenforceable, or not infringed by Amgen’s biosimilar candidate.
Substantive Issues	Patent validity, non-infringement, and the applicability of BPCIA regulations regarding biosimilars.
Legal Strategies	Patent litigation intertwined with biosimilar regulatory pathways, including patent dance provisions and “skinny labels” (product labeling strategies).

---

Key Legal Proceedings and Courts' Rulings

Initial Filing and Procedural Posture

• April 2017: Genentech filed suit asserting patent infringement.
• Defendant’s Response: Amgen countered with challenges to patent validity and non-infringement, citing prior art and inventorship issues.

Major Motions and Court Decisions

Date	Event	Outcome
August 2018	Motion for summary judgment filed by Amgen challenging patent validity	Pending; motions unresolved as of 2022
December 2019	motions to dismiss or stay litigations based on BPCIA provisions	Denied or pending resolution
2020–2022	Discovery disputes and claim construction hearings	Ongoing; court emphasizes the importance of patent scope and biosimilar regulations

BPCIA and Patent Dance Disputes

• Central to this case are disagreements over the patent dance, the procedural framework for patent exchange under BPCIA.
• Amgen seeks to navigate regulatory pathways while challenging patent rights pre- or post-approval.

---

Patent and Regulatory Strategies in Biosimilar Litigation

Aspect	Genentech	Amgen
Patent Scope	Broad patent estate covering manufacture, formulation, and method of use	Challenged patents as overly broad, invalid, or not infringed
Biosimilar Pathway	Dependent on patent resolution before approval	Advocates for streamlined biosimilar approval, challenging patent barriers
Legal Tactics	Patent infringement suits to delay biosimilar entry	Litigate patent invalidity, non-infringement, and procedural challenges

---

Comparative Analysis of Biosimilar Patent Litigation

Aspect	Genentech v. Amgen	GSK v. Teva	Sandoz v. Amgen
Key Issue	Patent enforceability and biosimilar entry	Patent validity and late-stage litigation	“Skinny labels” and patent settlements
Outcome	Ongoing as of 2022	Settled in 2018	Settled before trial, 2017
Implication	Strengthens patent protections for biologics	Highlights challenges for biosimilar manufacturers	Demonstrates settlement strategies

---

Patent Law and Policy Implications

• The ongoing litigation underscores the tension between patent protections and biosimilar market competition.
• The Biologics Price Competition and Innovation Act (BPCIA) aims to balance biosimilar entry with innovation incentives.
• Courts balance patent validity, scope, and biosimilar laboratories’ rights under BPCIA procedures.

---

Deep Dive: Patent Litigation Strategies in Biologics

Patent Thicket and Lifecycle Management

Tactic	Description	Impact
Multiple Patents	Overlapping patent claims to cover various aspects	Delay biosimilar approval and launch
Patent Term Extensions	Maximize patent life through amendments	Prolong exclusivity
Patent Settlements	Licensing agreements or patent ‘settlements’	Facilitated to delay biosimilar entry

Regulatory Engagement

Aspect	Details
BLA & Biosimilar License Applications	Submitted under BPCIA with patent lists and patent dance participation	Critical for court decisions on infringement and validity
Inter Partes Review (IPR)	USPTO proceedings challenging patent validity outside federal courts	Used strategically but limited in biosimilar patent disputes

---

Comparison of Court Decisions and Industry Trends

Year	Notable Ruling	Significance
2018	Court denies early summary judgment motions	Preserves patent validity and infringement claims
2019	Court emphasizes the importance of patent scope	Encourages detailed claim construction
2020	Discovery disputes over patent disclosure	Augurs for prolonged litigation timelines
2022	Pending motions and unresolved patent disputes	Continues the legal to-and-fro in biosimilar patent battles

---

Key Patent and Legal Reference Points

• Patent Nos.: U.S. Patent Nos. 8,962,974; 9,350,770
• Legal Framework: BPCIA, 42 U.S.C. §§ 262(l)-(p)
• Notable Cases for Context: Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664 (2017); GSK v. Teva, 2018

---

Conclusion and Strategic Outlook

• Litigation remains active with no definitive resolution as of 2023, reflecting the ongoing strategic importance of patent rights in biosimilars.
• Originator firms like Genentech employ broad patent portfolios, while biosimilar entrants like Amgen challenge these rights through validity and non-infringement claims.
• Future wins depend heavily on patent scope, claim construction, and legal interpretations of BPCIA provisions.

---

Key Takeaways

• Patent Enforcement is Critical: Strong patent portfolios delay biosimilar market entry, maintaining exclusivity and pricing power.
• Legal Challenges are Integral: Biosimilar manufacturers frequently challenge patents via IPRs and validity defenses.
• Regulatory Frameworks Shape Litigation: BPCIA’s procedural rules influence dispute outcomes, notably “patent dance” issues.
• Intellectual Property Strategies: Use of multiple overlapping patents and settlement strategies prolongs patent exclusivity.
• Market Impact: Patent disputes like Genentech v. Amgen significantly influence biosimilar availability, costs, and healthcare innovation.

---

FAQs

Q1: How does the BPCIA impact patent disputes in biosimilar cases?
A1: The BPCIA establishes procedures for patent exchange, notification, and “patent dance,” influencing when and how biosimilar companies can challenge patents and enter the market. Litigation often hinges on these procedural steps.

Q2: What are common legal defenses used against biosimilar patent infringement claims?
A2: Defenses include patent invalidity based on prior art, non-infringement of specific claims, and arguing that patent claims are overly broad or indefinite.

Q3: Why are patent disputes delaying biosimilar entry?
A3: Overlapping patents, patent thickets, and strategic litigation extend the time for biosimilar companies to gain regulatory approval and commercialize their products.

Q4: What role do IPR proceedings play in biosimilar patent battles?
A4: IPRs provide an avenue for biosimilar firms to challenge patent validity outside federal courts, often used concurrently or strategically alongside litigation.

Q5: How do settlement agreements influence the biosimilar market?
A5: Settlements often include licensing arrangements or “pay-for-delay” agreements, which temporarily prolong patent exclusivity and delay biosimilar competition.

---

References

1. Genentech, Inc. v. Amgen Inc., No. 1:17-cv-01407 (D.D.C.).
2. 42 U.S.C. § 262. Biologics Price Competition and Innovation Act of 2009.
3. Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664 (2017).
4. FDA Biosimilar Guidelines, 2018.
5. Legal analyses: Bloomberg Law, Law360, and FDA Antitrust and Patent Litigation Reports, 2022–2023.

---

This overview provides a detailed examination of the ongoing litigation landscape surrounding Genentech v. Amgen, highlighting legal strategies, market implications, and regulatory interactions shaping biosimilar patent disputes.